Obesity Drug Labeling Updated with New Interaction, Side Effect

The Food and Drug Administration (FDA) has approved a supplemental New Drug Application for Xenical (obesity management drug) regarding new drug interactions and adverse reaction updates to its labeling. Xenical is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. The product labeling has been updated to include a possible drug interaction with amiodarone (treats life-threatening heart rhythm problems). Via MPR. Posted August 17, 2015.

–Alanna McCatty

DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.

While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual's medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.

Was This Article Helpful?

Show Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments